SAN DIEGO, March 27, 2018 /PRNewswire/ -- Renova™ Therapeutics, a biotechnology company developing gene and peptide-based treatments for cardiovascular and metabolic diseases, announced today that the European Patent Office has issued Patent No. 2814513, "Systemic Delivery and Regulated Expression of Paracrine Genes for Cardiovascular Diseases and Other Conditions" to The Regents of the University of California. Renova Therapeutics holds a worldwide exclusive license to this intellectual property. This patent protects the use of vectors containing paracrine genes for delivery of gene therapy for cardiovascular diseases. In addition, a patent has been granted by the Russian Patent office (Patent No. 2642605) directed to broad methods of gene therapy using paracrine genes for treatment of cardiovascular diseases and diabetes. Both of these patents will expire in February, 2033.
"This is a significant and exciting decision by the European and Russian Patent Offices, and we view this announcement as recognition of Renova's important contributions to the gene therapy field," stated Dr. Jack W. Reich, CEO and Co-founder of Renova Therapeutics. "This patent provides protection for our paracrine delivery method, which has the potential to allow patients to be treated for serious cardiovascular diseases in a non-invasive manner."
With Renova's paracrine method of delivery, doctors may be able to administer gene therapies via IV injection, rather than through more invasive means of delivery. Delivery of gene therapy via IV injection may allow for therapies to be delivered on an outpatient basis, with a commensurate reduction in hospitalization time and cost.
About Renova Therapeutics
Renova Therapeutics is developing definitive, one-time gene therapies and peptide infusion treatments to restore the health of people suffering from chronic diseases. The first indications the company is pursuing are gene therapy treatments for heart failure and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead product candidate, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with heart failure. The company's product pipeline also includes a groundbreaking gene therapy in preclinical stage for sufferers of type 2 diabetes, as well as a peptide infusion therapy for the treatment of acute decompensated heart failure. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.
SOURCE Renova Therapeutics